HMBT.OB: Summary for HEMOBIOTECH INC - Yahoo! Canada Finance

MORE ON HMBT.OB

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

HEMOBIOTECH INC (OTC BB:HMBT.OB) Delayed quote data

Last Trade:	0.35 USD
Trade Time:	2:56PM EST
Change:	0.00 (0.00%)
Prev Close:	0.35
Open:	0.22
Bid:	0.25 x 5000
Ask:	0.35 x 5000
1y Target Est:	N/A

Day's Range:	0.22 - 0.35
52wk Range:	0.15 - 1.01
Volume:	8,051
Avg Vol (3m):	3,106.35
Market Cap:	7.14M
P/E (ttm):	N/A
EPS (ttm):	-0.21
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Add HMBT.OB to Portfolio

Download Data

HEADLINES

•	HEMOBIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers
	EDGAR Online (Wed, Jan 6)

•	HEMOBIOTECH, INC. Financials
	EDGAR Online Financials (Thu, Dec 10)

•	HEMOBIOTECH, INC. Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Thu, Dec 3)

•	HEMOBIOTECH, INC. Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Thu, Dec 3)

•	HEMOBIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers
	EDGAR Online (Thu, Oct 29)

•	HEMOBIOTECH, INC. Financials
	EDGAR Online Financials (Thu, Aug 27)

•	HEMOBIOTECH, INC. Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Tue, Aug 18)

•	HEMOBIOTECH, INC. Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Tue, Aug 18)

•	HemoBioTech Gains Congressional Recognition of Its Blood Substitute Technology
	Marketwire (Mon, Aug 17)

•	HemoBioTech to Present "Need for Blood Substitute to Prevent HIV Transmission" at 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
	Marketwire (Tue, Jun 2)

More Headlines for HMBT.OB...

BUSINESS SUMMARY

HemoBioTech, Inc., a development stage biopharmaceutical company, engages in the research and development of human blood substitute technology licensed from Texas Tech University Health Science Center School of Medicine (TTUHSC) in Texas.

Full Company Profile

Add to Portfolio

Email to a Friend

•

	Sign In [New User? Sign Up]	Finance Home \|Help

Hemobiotech Inc. (HMBT.OB)